Abstract
Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / immunology*
-
Antineoplastic Agents / adverse effects*
-
Child
-
Humans
-
Meningoencephalitis / chemically induced*
-
Middle Aged
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
Rituximab